It's still too early to say whether UiPath will ultimately end up, on net, as benefitting from or being harmed by AI adoption. Read why PATH stock is a Sell.

UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.

"We're also providing a scalable blueprint to expand agentic automation across the enterprise, transforming how business users engage with ERP through seamless collaboration betwe ...

Morgan Stanley analyst Sanjit Singh also trimmed his price target to $17 from $19. ・Analysts say fourth-quarter results met expectations but see limited near-term upside due to modest growth. ・UBS ...

Utopai Studios built a professional-grade cinematic engine that produces stunning long-form AI video—but its learning curve ...

UiPath stock has tumbled as optimism around its automation software has been overtaken by concern about artificial intelligence.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries.